Skip to main content
. 2023 Jan 9;13:419. doi: 10.1038/s41598-022-27090-1

Figure 2.

Figure 2

Zoledronic acid declines the population of PGCCs pre- and post-cisplatin administration. (A) DNA content analysis of 5637 bladder cancer cells treated with different doses of ZA indicates the reduction of PGCCs post-treatment. (B) Cisplatin administration enriches PGCCs and ZA at different doses from 10–600 μM declines the PGCC population with the most profound effect being observed at 50 μM. *p-value < 0.05; ** p- value < 0.01; error bars: mean ± SEM.